Since insulin resistance is considered as a main pathogenetic factor for the development of NAFLD, pharmacological strategies to improve insulin sensitivity have been investigated as potential treatment options for NAFLD, but the studies have yielded conflicting results [56]. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.